Predictive Oncology Announces Appointment of Oncology Translational Research Leader Christoph Reinhard, Ph.D., MBA, to its Scientific Advisory Board

Predictive Oncology a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, is pleased to announce the appointment of Christoph Reinhard, Ph.D., MBA, to its Scientific Advisory Board. In this role, Dr. Reinhard will serve alongside other key thought leaders in their respective fields to guide the Company’s scientific initiatives and growth strategy.

Recommended AI: GoodFirms Unlocks the Best Task Management Software with Rich Features

Dr. Reinhard is a leader in oncology translational research, new technologies in drug development, and external innovation. As acting Chief Scientific Officer for CELLphenomics GmbH, he plays an instrumental role in determining what types of novel drugs and drug combinations might be beneficial to future cancer patients with solid tumors.

“We are fortunate to have someone on our Scientific Advisory Board with such extensive experience in the biopharmaceutical industry with a deep understanding of oncology and translational science,” said Raymond F. Vennare, Chief Executive Officer of Predictive Oncology. “Dr. Reinhard’s personal and professional commitment is both impressive and honorable, and his insights into oncology drug development will prove invaluable as we continue to gain momentum with oncology drug development partners around the world.”

“I am excited about the opportunities that Predictive Oncology offers in drug discovery and the advancements its scientists have made in partnering with biopharmaceuticals to bring cancer therapies forward,” noted Dr. Reinhard. “Predictive Oncology has a breakthrough technology with their PEDAL platform that can significantly accelerate early drug discovery and positively impact oncology drug development.”

Recommended AI: aelf Announces the form of aelf DAO, Enhancing Decentralization of Governance and Ecosystem Growth

For more than a decade, Dr. Reinhard worked at Eli Lilly where he was responsible for strategy development and implementation of translational research support for its oncology portfolio assets, as well as the cross-functional alignment and resourcing of oncology biomarker efforts. He spearheaded the company’s Innovative Medicine Initiative in Oncology and was directly involved in the development and implementation of the Partners and Outsourcing Strategy for Lilly Singapore’s drug development and biomarker efforts. He is also the co-founder and Director of the Board of Asian Cancer Research Group (ACRG).

Dr. Reinhard holds a Ph.D. from the Biocenter University, Basel, Switzerland; an MBA in Technology Management from Phoenix University; and a Bachelor of Science in Molecular Biology, Biochemistry and Microbiology from the University of Freiburg in Germany.

Recommended AI: Adelante Enhances Capabilities with Zendesk Setup Solution

[To share your insights with us, please write to sghosh@martechseries.com]